HK1080713A1 - Stable pharmaceutical composition containing factor viii - Google Patents

Stable pharmaceutical composition containing factor viii

Info

Publication number
HK1080713A1
HK1080713A1 HK06100540.9A HK06100540A HK1080713A1 HK 1080713 A1 HK1080713 A1 HK 1080713A1 HK 06100540 A HK06100540 A HK 06100540A HK 1080713 A1 HK1080713 A1 HK 1080713A1
Authority
HK
Hong Kong
Prior art keywords
pharmaceutical composition
composition containing
factor viii
stable pharmaceutical
containing factor
Prior art date
Application number
HK06100540.9A
Other languages
English (en)
Inventor
Mary White
Paul Webb
Original Assignee
Ipsen Pharma Sas
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ipsen Pharma Sas filed Critical Ipsen Pharma Sas
Publication of HK1080713A1 publication Critical patent/HK1080713A1/xx

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36Blood coagulation or fibrinolysis factors
    • A61K38/37Factors VIII
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02Inorganic compounds

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Dermatology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Diabetes (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
HK06100540.9A 2002-03-26 2006-01-13 Stable pharmaceutical composition containing factor viii HK1080713A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0207092.8A GB0207092D0 (en) 2002-03-26 2002-03-26 Stable pharmaceutical composition containing factor VIII
PCT/GB2003/001297 WO2003080108A1 (en) 2002-03-26 2003-03-26 Stable pharmaceutical composition containing factor viii

Publications (1)

Publication Number Publication Date
HK1080713A1 true HK1080713A1 (en) 2006-05-04

Family

ID=9933726

Family Applications (2)

Application Number Title Priority Date Filing Date
HK06100540.9A HK1080713A1 (en) 2002-03-26 2006-01-13 Stable pharmaceutical composition containing factor viii
HK13110894.1A HK1183446A1 (en) 2002-03-26 2013-09-24 Stable pharmaceutical composition containing factor viii viii

Family Applications After (1)

Application Number Title Priority Date Filing Date
HK13110894.1A HK1183446A1 (en) 2002-03-26 2013-09-24 Stable pharmaceutical composition containing factor viii viii

Country Status (27)

Country Link
US (1) US7790680B2 (es)
EP (2) EP1490095B1 (es)
JP (4) JP2005530714A (es)
KR (1) KR20040093482A (es)
CN (2) CN1642570B (es)
AR (1) AR039123A1 (es)
AT (1) ATE477814T1 (es)
AU (1) AU2003217030B2 (es)
BR (1) BR0308442A (es)
CA (1) CA2480226C (es)
DE (1) DE60333825D1 (es)
DK (1) DK1490095T3 (es)
ES (1) ES2350337T3 (es)
GB (1) GB0207092D0 (es)
HK (2) HK1080713A1 (es)
HR (1) HRP20040882B1 (es)
IL (2) IL163849A0 (es)
IS (1) IS7458A (es)
MX (1) MXPA04009275A (es)
MY (1) MY149831A (es)
NO (1) NO328450B1 (es)
NZ (1) NZ535032A (es)
PL (1) PL208009B1 (es)
PT (1) PT1490095E (es)
RU (1) RU2314825C2 (es)
TW (1) TWI285106B (es)
WO (1) WO2003080108A1 (es)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7560107B2 (en) 1996-06-26 2009-07-14 Emory University Modified factor VIII
BR0315782A (pt) * 2002-10-29 2005-09-20 Alza Corp Partìculas de polipeptìdeo em estado sólido, estabilizadas
JP4644663B2 (ja) 2003-06-03 2011-03-02 セル ジェネシス インコーポレイテッド ペプチド開裂部位を用いた単一ベクターからの組換えポリペプチドの高められた発現のための構成と方法
US7485291B2 (en) 2003-06-03 2009-02-03 Cell Genesys, Inc. Compositions and methods for generating multiple polypeptides from a single vector using a virus derived peptide cleavage site, and uses thereof
AU2004288854B2 (en) * 2003-11-10 2009-10-01 Arriva-Pharmaceuticals, Inc. Dry recombinant human alpha 1-antitrypsin formulation
EP1750733B1 (en) 2004-05-03 2013-12-11 Emory University METHOD OF ADMINISTERING PORCINE B-DOMAINLESS fVIII
EP2268267B1 (en) * 2008-04-21 2017-06-14 Novo Nordisk Health Care AG Dry transglutaminase composition
EP2113564A1 (en) 2008-05-01 2009-11-04 Arecor Limited Protein formulation
AU2009284113B2 (en) 2008-08-21 2015-05-14 Octapharma Ag Recombinantly produced human factor VIII and IX
CN102143759A (zh) * 2008-09-03 2011-08-03 奥克塔法马股份有限公司 重组制备的因子ⅷ的新型保护组合物
JP5779780B2 (ja) 2008-11-07 2015-09-16 バクスター・インターナショナル・インコーポレイテッドBaxter International Incorp0Rated 第viii因子製剤
GB0915480D0 (en) * 2009-09-04 2009-10-07 Arecor Ltd Stable formulation of factor viii
SG10201509149VA (en) 2010-11-05 2015-12-30 Baxter Int A new variant of antihemophilic factor viii having increased specific activity
AU2014237111B2 (en) * 2013-03-15 2018-06-21 Bayer Healthcare Llc Recombinant factor VIII formulations
UY35462A (es) 2013-03-15 2014-10-31 Biogen Idec Inc Formulación de un polipéptido del factor viii.
BR112017002090B1 (pt) 2014-08-04 2021-06-01 Csl Limited Composição aquosa de fator viii de coagulação e método de estabilizar uma molécula de fviii
JP6781508B2 (ja) * 2014-11-18 2020-11-04 塩野義製薬株式会社 安定化されたペプチド組成物
CN114072420B (zh) 2019-07-04 2024-06-11 康诺贝林伦瑙有限公司 用于增加凝血因子viii的体外稳定性的截短的血管性血友病因子(vwf)
EP4240757A2 (en) 2020-11-09 2023-09-13 Takeda Pharmaceutical Company Limited Purification of fviii from plasma using silicon oxide adsorption

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6281327A (ja) * 1985-10-04 1987-04-14 Green Cross Corp:The 人トロンビン製剤の加熱処理方法
JPS6485927A (en) 1987-09-29 1989-03-30 Green Cross Corp Hepatitis b vaccine
US5605884A (en) 1987-10-29 1997-02-25 Rhone-Poulenc Rorer Pharmaceuticals Inc. Factor VIII formulations in high ionic strength media
WO1989009784A1 (en) 1988-04-08 1989-10-19 Commonwealth Serum Laboratories Commission Production of heat-stable factor viii concentrate
SE465222C5 (sv) 1989-12-15 1998-02-10 Pharmacia & Upjohn Ab Ett rekombinant, humant faktor VIII-derivat och förfarande för dess framställning
IE64738B1 (en) * 1990-03-20 1995-09-06 Akzo Nv Stabilized gonadotropin containing preparations
DE4111393A1 (de) 1991-04-09 1992-10-15 Behringwerke Ag Stabilisierte faktor viii-praeparationen
ATE198277T1 (de) 1992-10-02 2001-01-15 Genetics Inst Zusammensetzung, welche den koagulationsfaktor viii beinhaltet; verfahren zu deren herstellung und die benutzung eines oberflächenaktiven stoffes als stabilisator
SE9301581D0 (sv) 1993-05-07 1993-05-07 Kabi Pharmacia Ab Protein formulation
SE504074C2 (sv) 1993-07-05 1996-11-04 Pharmacia Ab Proteinberedning för subkutan, intramuskulär eller intradermal administrering
ZA955642B (en) * 1994-07-07 1997-05-06 Ortho Pharma Corp Lyophilized imaging agent formulation
JPH0899999A (ja) 1994-09-30 1996-04-16 Chemo Sero Therapeut Res Inst α1プロテアーゼインヒビターの製造方法
US6458563B1 (en) 1996-06-26 2002-10-01 Emory University Modified factor VIII
US5763401A (en) 1996-07-12 1998-06-09 Bayer Corporation Stabilized albumin-free recombinant factor VIII preparation having a low sugar content
RU2244556C2 (ru) 1999-02-22 2005-01-20 Юниверсити Оф Коннектикут Новые не содержащие альбумин составы фактора viii
JP4674021B2 (ja) 1999-07-13 2011-04-20 ビオヴィトルム・アクチボラゲット(プブリクト) 安定第viii因子組成物
AU6558400A (en) * 1999-08-17 2001-03-13 Novo Nordisk A/S Stabilisation of freeze-dried cake
US6586574B1 (en) * 1999-08-17 2003-07-01 Nn A/S Stabilization of freeze-dried cake
US7282562B2 (en) * 1999-08-31 2007-10-16 Genentech, Inc. Compositions and methods for the treatment of immune related diseases

Also Published As

Publication number Publication date
IS7458A (is) 2004-09-17
CA2480226A1 (en) 2003-10-02
AR039123A1 (es) 2005-02-09
NZ535032A (en) 2006-03-31
RU2314825C2 (ru) 2008-01-20
ES2350337T3 (es) 2011-01-21
ATE477814T1 (de) 2010-09-15
NO20044305L (no) 2004-10-11
PL208009B1 (pl) 2011-03-31
MXPA04009275A (es) 2005-01-25
DE60333825D1 (de) 2010-09-30
HK1183446A1 (en) 2013-12-27
IL163849A0 (en) 2005-12-18
EP2292216A2 (en) 2011-03-09
CN103006540A (zh) 2013-04-03
CA2480226C (en) 2012-09-18
EP1490095A1 (en) 2004-12-29
EP1490095B1 (en) 2010-08-18
CN1642570B (zh) 2013-01-09
HRP20040882A2 (en) 2004-12-31
NO328450B1 (no) 2010-02-22
PL372414A1 (en) 2005-07-25
WO2003080108A1 (en) 2003-10-02
JP2011079862A (ja) 2011-04-21
GB0207092D0 (en) 2002-05-08
DK1490095T3 (da) 2010-11-08
AU2003217030A1 (en) 2003-10-08
AU2003217030B2 (en) 2008-12-04
US7790680B2 (en) 2010-09-07
IL163849A (en) 2010-12-30
CN103006540B (zh) 2015-09-16
JP2013147508A (ja) 2013-08-01
TWI285106B (en) 2007-08-11
JP2005530714A (ja) 2005-10-13
KR20040093482A (ko) 2004-11-05
RU2004131556A (ru) 2005-08-20
JP2015143245A (ja) 2015-08-06
MY149831A (en) 2013-10-31
PT1490095E (pt) 2010-10-21
BR0308442A (pt) 2005-01-18
US20050256038A1 (en) 2005-11-17
EP2292216A3 (en) 2011-05-11
TW200304827A (en) 2003-10-16
JP5770775B2 (ja) 2015-08-26
CN1642570A (zh) 2005-07-20
HRP20040882B1 (hr) 2013-02-28

Similar Documents

Publication Publication Date Title
HK1183446A1 (en) Stable pharmaceutical composition containing factor viii viii
GB2389530B (en) Pharmaceutical compositions
AU2003291103A8 (en) Pharmaceutical composition
GB2394894B (en) New use for pharmaceutical composition
IL164547A0 (en) Pharmaceutical composition
GB2391473B (en) Pharmaceutical compositions
AU2003250372A8 (en) Pharmaceutical composition
GB0213481D0 (en) Pharmaceutical compositions
HK1081451A1 (en) Medicinal composition
EP1480649A4 (en) STABLE PHARMACEUTICAL COMPOSITIONS
HK1065477A1 (en) Pharmaceutical composition
HK1062274A1 (en) Medicinal composition
PL370907A1 (en) Pharmaceutical compositions
HU0200337D0 (en) Stabilised pharmaceutical composition
GB0217703D0 (en) Pharmaceutical composition
EP1547593A4 (en) MEDICINAL COMPOSITION
EP1531867A4 (en) METASTABLE PHARMACEUTICAL COMPOSITIONS
GB0214491D0 (en) Pharmaceutical composition
GB0225042D0 (en) Pharmaceutical composition
GB0213306D0 (en) Pharmaceutical composition
GB0213305D0 (en) Pharmaceutical composition
GB0210238D0 (en) Pharmaceutical composition
GB0213267D0 (en) Pharmaceutical composition
GB0210905D0 (en) Pharmaceutical composition
GB0201891D0 (en) Pharmaceutical composition

Legal Events

Date Code Title Description
PE Patent expired

Effective date: 20230328